CXCR4 and breast cancer: Overall, these data show that interfering with the CXCL12/CXCR4 axis provides a means to therapeutically impact BC stemness and suggest that focused targeting of CAFs that provide the CXCL12-dependent niche could stall metastasis and relapse in BC.